BMRA
BIOMERICA INC
-0.01 (-0.43%)2.36USD33.1K成交股數10.8M市值–本益比(近四季)2.4股價營收比-11.8%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 5 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 876K-22% | 987K-40% | 1.2M-33% | 1.4M+23% | 1.1M+10% | 1.6M+4% | 1.8M+5% | 1.1M+1% | 1.0M | 1.6M | 1.7M | 1.1M |
| 營業成本 | 945K | 1.0M | 1.2M | 956K | 1.1M | 1.2M | 1.5M | 1.1M | 1.2M | 1.2M | 1.3M | 991K |
| 毛利 | −69K-463% | −44K-110% | 51K-82% | 424K+1743% | 19K-113% | 437K+34% | 289K-30% | 23K-81% | −149K | 325K | 412K | 120K |
| 毛利率 | -7.9% | -4.5% | 4.2% | 30.7% | 1.7% | 26.7% | 16.0% | 2.1% | -14.7% | 20.7% | 24.1% | 10.8% |
| 研發費用 | 205K | 178K | 193K | 212K | 217K | 257K | 297K | 264K | 343K | 412K | 472K | 392K |
| 銷售管理費用 | 1.3M | 1.1M | 1.2M | 1.3M | 1.0M | 1.2M | 1.4M | 1.3M | 1.5M | 1.5M | 1.2M | 1.4M |
| 營業利益 | −1.5M+27% | −1.3M+31% | −1.4M+0% | −1.1M-27% | −1.2M-40% | −993K-38% | −1.4M+11% | −1.5M-8% | −2.0M | −1.6M | −1.2M | −1.7M |
| 營業利益率 | -174.8% | -131.5% | -113.5% | -81.0% | -108.1% | -60.7% | -75.7% | -136.6% | -196.7% | -102.6% | -71.9% | -148.6% |
| 稅後淨利 | −1.1M-2% | −1.3M+38% | −1.3M+0% | 2K-100% | −1.2M-39% | −950K-37% | −1.3M+16% | −1.4M-14% | −1.9M | −1.5M | −1.1M | −1.7M |
| 淨利率 | -130.7% | -132.9% | -109.1% | 0.1% | -103.9% | -58.1% | -72.8% | -127.1% | -188.6% | -96.2% | -66.1% | -148.5% |
| 稀釋 EPS | -0.41-15% | -0.44+633% | -0.45-29% | 0.00-100% | -0.48+336% | -0.06-33% | -0.63+800% | -2.57+2042% | -0.11 | -0.09 | -0.07 | -0.12 |
| 稀釋股數 | 2.9M | 3.0M | 2.9M | 2.6M | 2.4M | 2.1M | 2.1M | 2.1M | 16.8M | 16.8M | 16.8M | 13.5M |
資產負債表 期末餘額
| 科目 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.3M | 1.3M | 2.5M | 3.1M | 3.1M | 2.4M | 2.8M | 4.2M | 5.3M | 7.1M | 8.0M | 3.3M |
| 應收帳款 | 785K | 941K | 947K | 1.2M | 1.3M | 1.3M | 1.6M | 947K | 1.1M | 1.1M | 1.4M | 755K |
| 存貨 | 1.7M | 1.6M | 1.5M | 1.5M | 1.7M | 1.8M | 1.9M | 2.4M | 2.1M | 1.8M | 1.9M | 2.1M |
| 總資產 | 6.8M | 4.9M | 6.0M | 6.9M | 7.4M | 7.3M | 7.9M | 9.3M | 10.3M | 11.8M | 13.2M | 8.2M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 4.1M | 1.6M | 1.6M | 1.7M | 1.8M | 2.2M | 2.5M | 2.7M | 2.5M | 2.4M | 2.5M | 2.2M |
| 股東權益 | 2.6M | 3.3M | 4.4M | 5.2M | 5.5M | 5.1M | 5.3M | 6.6M | 7.8M | 9.4M | 10.8M | 6.0M |
| 負債比 | 61.1% | 32.0% | 26.5% | 24.8% | 25.0% | 29.7% | 32.1% | 28.8% | 24.5% | 20.7% | 18.5% | 27.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q4 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | – | −268K | – | – | −1.3M-20% | – | – | – | −1.7M | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | 21K | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | −1.7M | – |
| 折舊攤銷 | – | – | – | 20K | – | – | 21K | – | – | – | 21K | 15K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | -98.9% | – |
營收拆解 2026 年度 10-K 的分部揭露 · 年增對前一年度
地區2026 年度 · 4.5M
| North America | 1.5M | 32.9% | -11.6% |
|---|---|---|---|
| 亞洲 | 1.4M | 31.6% | -18.0% |
| 歐洲 | 1.1M | 25.1% | -13.9% |
| Middle East | 446K | 10.0% | -29.2% |
| South America | 15K | 0.3% | +87.5% |
產品／服務2026 年度 · 4.5M
| Clinical Lab | 2.7M | 61.4% | -14.1% |
|---|---|---|---|
| Contract Manufacturing | 891K | 20.0% | -16.7% |
| Over The Counte | 821K | 18.4% | -21.7% |
| Physicians Office | 9K | 0.2% | -18.2% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2026 | 4.5M | -16.2% | −3.8M | -84.8% | -1.30 | – |
| FY2025 | 5.3M | -1.9% | −5.0M | -93.6% | -2.16 | – |
| FY2024 | 5.4M | +1.4% | −6.0M | -110.4% | -2.84 | −5.4M |
| FY2023 | 5.3M | -71.7% | −7.1M | -133.7% | -0.50 | −5.5M |
| FY2022 | 18.9M | +162.1% | −4.5M | -24.0% | -0.36 | −536K |
| FY2021 | 7.2M | +7.6% | −7.4M | -103.4% | -0.62 | −5.4M |
| FY2020 | 6.7M | +28.7% | −2.7M | -40.0% | -0.26 | −4.3M |
| FY2019 | 5.2M | – | −2.4M | -46.0% | -0.26 | −2.3M |